Letter |

Letter to Roche. Access to Viracept in China

Mrs Maria Vigneau Director of external relations for HIV/AIDS

Dear Mrs Vigneau,

MSF began antiretroviral treatment in 2001 and is now treating more than 34,000 patients in 28 countries. In our project in China we have over 200 patients receiving ARV, all of them on first line treatment. Nevertheless, we expect to have some patients on second-line regimens in the near future. As you know, nelfinavir (Viracepte) is one of the WHO recommended second-line drugs.

According to the information coming from the Chinese State Food and Drug Administration (SFDA), Viracept ® is registered but not marketed.

Not only is MSF concerned about access to Viracept ® at affordable price for our projects, but about access for the entire Chinese population. By neglecting to make its products available on the Chinese market, Roche is failing to fulfill its commitment to broadening "access by providing HIV care products at a loss" to the "programs that need them most".

We therefore urge Roche to market Viracept® in China at the price offered to developing countries: US$949 per year (FOB).

Thank you in advance for your cooperation in responding to our letter. We hope we will be able to discuss some of these issues in the meeting we will probably have in September. We look forward to hearing from you at your earliest possible convenience. 

Fernando Pascual Marinez
HIV Focal Pharmacist
MSF Access Campaign for Access to Essential Medicines

Elodie Jambert
Field Pharmacist, MSF China Project